Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis

Assistance Publique - Hôpitaux de Paris200 enrolled

Overview

Inhalation of beryllium can induce specific sensitization and diffuse pulmonary granulomatosis called chronic beryllium disease (CBD). The clinical, radiographic, and anatomopathological features of CBD are very similar to those of sarcoidosis, another granulomatosis, making its diagnosis difficult. In addition, the progression of CBD is poorly understood. The investigators hypothesis is that there are specific clinical, biological, anatomopathological, and radiological presentation specificities of CBD, as well as a worse prognosis compared to pulmonary sarcoidosis.

Inhalation of beryllium can induce specific sensitization and diffuse pulmonary granulomatosis called chronic beryllium disease (CBD). The clinical, radiographic, and anatomopathological features of CBD are very similar to those of sarcoidosis, another granulomatosis, making its diagnosis difficult. In addition, the progression of CBD is poorly understood . The investigators hypothesis is that there are specific clinical, biological, anatomopathological, and radiological presentation specificities of CBD, as well as a worse prognosis compared to pulmonary sarcoidosis.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Pulmonary Sarcoidosis Chronic Beryllium Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years * Sufficiently documented medical record. * Informed patients who did not object to participating in the research, or for deceased patients, did not object to the use of their data. * Cases: Patients followed for confirmed chronic beryllium disease by expert teams based on the ATS 2014 criteria, i.e., a history of exposure to beryllium, positivity of two abnormal lymphocyte proliferation tests (LPT) in blood and/or an abnormal LPT in bronchoalveolar lavage, granuloma found in pulmonary biopsy associated by compatible clinical, radiological or spirometric abnormalities. * Controls: Patients followed for sarcoidosis according to the ATS/ERS/WASOG criteria, i.e., (i) a compatible presentation, (ii) the presence of non-necrotizing granulomatosis in one or more tissues (except Löfgren's syndrome or Heerfordt syndrome), (iii) and exclusion of alternative causes of granulomatous diseases with pulmonary parenchymal involvement on thoracic CT and/or chest radiography. * Controls: without occupational exposure to beryllium. Exclusion Criteria: * Patients under trustee.

Outcomes

Primary Outcomes

The phenotypic profile at inclusion will be based on clinical data

symptoms at diagnosis

Time frame: baseline

The phenotypic profile at inclusion will be based on clinical data

general signs(number and type of organs affected)

Time frame: baseline

The phenotypic profile at inclusion will be based on biological data

serum angiotensin-converting enzyme assay (hydrolysis of one micromole of substrate per minute)

Time frame: baseline

The phenotypic profile at inclusion will be based on biological data

blood calcium(mmol/L)

Time frame: baseline

The phenotypic profile at inclusion will be based on biological data

calciuria (mmol/kg/J)

Time frame: baseline

The phenotypic profile at inclusion will be based on biological data

blood lymphocytes(mm3)

Time frame: baseline

The phenotypic profile at inclusion will be based on biological data

gamma globulinemia (g/L)

Time frame: baseline